Study objective: To compare the safety of salmeterol xinafoate or placebo added to usual asthma care. Design: A 28-week, randomized, double-blind, placebo-controlled, observational study.

Seretide (salmeterol xinafoate/fluticasone propionate) – sold as Advair in the US and other markets – is the top-selling inhaled beta agonist and corticosteroid combination therapy in the UK.

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...

Combination meds with an ICS and LABA option to relax and open airways, like Advair (fluticasone with salmeterol) Long-acting muscarinic agonists (LAMA) drugs, including Spiriva Respimat (tiotropium ...

3 Department of Statistics (Research & Development), King’s College Hospital, London, UK Correspondence to: Dr W D C Man Respiratory Muscle Laboratory, Guy’s, King’s and St Thomas’ School of Medicine, ...

Londamocitinib xinafoate is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate ...

A study was undertaken to investigate the efficacy and safety of long term treatment with salbutamol and salmeterol in patients with mild to moderate bronchial asthma. METHODS In a two centre double ...

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA), ...